CO2024006819A2 - Composiciones y tratamientos con nirogacestat - Google Patents

Composiciones y tratamientos con nirogacestat

Info

Publication number
CO2024006819A2
CO2024006819A2 CONC2024/0006819A CO2024006819A CO2024006819A2 CO 2024006819 A2 CO2024006819 A2 CO 2024006819A2 CO 2024006819 A CO2024006819 A CO 2024006819A CO 2024006819 A2 CO2024006819 A2 CO 2024006819A2
Authority
CO
Colombia
Prior art keywords
nirogacestat
compositions
treatments
present disclosure
pharmaceutically acceptable
Prior art date
Application number
CONC2024/0006819A
Other languages
English (en)
Inventor
Kristin Patterson
Shinta Cheng
Todd Webster Shearer
Rex Williams
Original Assignee
Springworks Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Springworks Therapeutics Inc filed Critical Springworks Therapeutics Inc
Publication of CO2024006819A2 publication Critical patent/CO2024006819A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente divulgación se refiere a composiciones y métodos de tratamiento que comprenden nirogacestat o una sal farmacéuticamente aceptable de este.
CONC2024/0006819A 2021-11-05 2024-05-28 Composiciones y tratamientos con nirogacestat CO2024006819A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163263635P 2021-11-05 2021-11-05
US202263365125P 2022-05-20 2022-05-20
US202263365193P 2022-05-23 2022-05-23
US202263369733P 2022-07-28 2022-07-28
PCT/US2022/079309 WO2023081830A2 (en) 2021-11-05 2022-11-04 Compositions and treatments with nirogacestat

Publications (1)

Publication Number Publication Date
CO2024006819A2 true CO2024006819A2 (es) 2024-06-07

Family

ID=86242233

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0006819A CO2024006819A2 (es) 2021-11-05 2024-05-28 Composiciones y tratamientos con nirogacestat

Country Status (4)

Country Link
AU (1) AU2022380837A1 (es)
CA (1) CA3237521A1 (es)
CO (1) CO2024006819A2 (es)
WO (1) WO2023081830A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
US20230372301A1 (en) 2022-05-20 2023-11-23 Springworks Therapeutics, Inc. Treatments with nirogacestat
US20240148695A1 (en) 2022-05-20 2024-05-09 Springworks Therapeutics, Inc. Treatments with nirogacestat

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015092614A1 (en) * 2013-12-20 2015-06-25 Pfizer Inc. Activating notch alterations in breast cancer
US10590087B1 (en) * 2019-08-09 2020-03-17 Pfizer Inc. Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
US20230112444A1 (en) * 2020-01-16 2023-04-13 Springworks Therapeutics, Inc. Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma secretase inhibitors
BR112022018987A2 (pt) * 2020-03-26 2022-11-01 Seagen Inc Métodos de tratamento de mieloma múltiplo

Also Published As

Publication number Publication date
WO2023081830A3 (en) 2023-06-08
CA3237521A1 (en) 2023-05-11
WO2023081830A2 (en) 2023-05-11
AU2022380837A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
CO2024006819A2 (es) Composiciones y tratamientos con nirogacestat
PE20221504A1 (es) Derivados de un inhibidor de fgfr
CL2021000400A1 (es) Métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
CL2023000767A1 (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto.
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
DOP2020000012A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
BR112018075682A2 (pt) inibidores de papd5 e papd7 para tratamento de infecção pela hepatite b
CL2022001217A1 (es) Métodos de tratamiento con modulador de la miosina
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
AR077629A1 (es) Mimetico de smac
CL2023001351A1 (es) Métodos de tratamiento de la insuficiencia cardíaca mediante la administración de omecamtiv mecarbil.
PE20191407A1 (es) Uso de gaboxadol en el tratamiento de tinnitus
CL2021000650A1 (es) Moduladores de la expresión de pnpla3
CO2021008816A2 (es) Moduladores de trex1
CL2008003201A1 (es) Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.
SV2017005418A (es) Inhibidor de cinasa aurora a
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
CL2023000289A1 (es) Combinaciones para el tratamiento de cáncer
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer